Rocket Pharmaceuticals, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Rocket Pharmaceuticals, Inc. (RCKT) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $146.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$27.95M.
- Rocket Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$113.83M.
- Rocket Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$20.64M.
- Rocket Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$75.94M.
- Rocket Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$86.10M, a 179.93% decline from fiscal 2024.
- Rocket Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $107.72M.
- Rocket Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$84.58M.
- Rocket Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$92.18M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $146.95M 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | -$27.95M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | -$86.10M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | -$87.68M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | -$130.81M 10-Q · filed 2026-08-10 | |||
| 2025-03-31 | -$113.83M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $107.72M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $9.69M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | -$17.31M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$20.64M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$84.58M 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $85.17M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | -$95.42M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | -$75.94M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$92.18M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | -$36.01M 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | -$45.15M 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | -$102.14M 10-Q · filed 2023-05-05 | |||
| 2021-12-31 | -$64.63M 10-K · filed 2024-02-27 | |||
| 2021-09-30 | -$51.69M 10-Q · filed 2022-11-04 | |||
| 2021-06-30 | -$32.72M 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | -$44.66M 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | $111.76M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | -$103.11M 10-Q · filed 2021-11-05 | |||
| 2020-06-30 | -$22.18M 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $5.14M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $74.12M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | -$22.07M 10-Q · filed 2020-11-06 | |||
| 2019-06-30 | -$46.43M 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | $13.20M 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | $94.44M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $21.37M 10-Q · filed 2019-11-08 | |||
| 2018-06-30 | $35.84M 10-Q · filed 2019-08-08 | |||
| 2018-03-31 | $153.00M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $8.68M 10-K · filed 2019-03-08 | |||
| 2017-09-30 | $14.70M 10-Q · filed 2018-11-09 | |||
| 2017-06-30 | $18.84M 10-Q · filed 2018-08-14 | |||
| 2016-12-31 | -$5.82M 10-K · filed 2019-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |